Survival and prognosis factors of lymphadenectomy in vulvar carcinoma: A tunisian single center study about 150 cases

Gadria, Selma; Slimane, Maher; Mansouri, Houyem; Charfi, Lamia; Safta, Inès Ben; Hechiche, M; Rahal, Khaled

doi:10.1016/j.jcrpr.2018.06.003

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many prognostic factors have been assessed in vulvar cancer including International Federation of Gynecology and Obstetrics (FIGO) stage, tumor size, invasion depth, capillary lymphatic space invasion, nodal metastases, extranodal spread, and positive or close margins . Similar to others malignancies, VSCC can escape from immune recognition .…”

Section: Introductionmentioning

confidence: 99%

HLA‐G, HLA‐E, and IDO overexpression predicts a worse survival of Tunisian patients with vulvar squamous cell carcinoma

Boujelbène

Yahia

Babay

et al. 2019

HLA

Self Cite

View full text Add to dashboard Cite

Little is known about non‐classical HLA molecules in vulvar squamous cell carcinoma (VSCC). Because of the indoleamine‐2,3‐dioxygenase (IDO) immune tolerant role in association with HLA‐G, we evaluated the clinical and prognostic value of HLA‐G, HLA‐E, and IDO in VSCC. HLA‐G, HLA‐E, and IDO expression was determined by immunohistochemistry in VSCC and associated with clinicopathological parameters and disease outcome. These three molecules were highly represented in tumoral tissues vs healthy matched vulvar tissues (P = 0.0001). Significant differences in HLA‐G expression in stages, tumor size, tumor invasion depth, and resection margins subgroups were reported (P < 0.05). At 5 years, the cumulative survival rates was of 79.8% in patients with HLA‐Glow expression vs 12.5% in those with HLA‐Ghigh expression (P < 3 × 10−5). Similarly, patients with IDOhigh expression were at a significantly reduced overall survival (OS) and disease‐free survival (DFS) rates (P = 0.011 and 0.045, respectively). The overexpression of the three molecules together worsen survival rates of VSCC patients (OS: P = 0.000038, DFS: P = 0.000085). Altogether, our results showed that HLA‐G, HLA‐E, and IDO may represent novel candidate markers for patients' prognosis and potential targets for VSCC therapy.

show abstract

Section: Introductionmentioning

confidence: 99%